NO20071161L - Kjemiske forbindelser - Google Patents
Kjemiske forbindelserInfo
- Publication number
- NO20071161L NO20071161L NO20071161A NO20071161A NO20071161L NO 20071161 L NO20071161 L NO 20071161L NO 20071161 A NO20071161 A NO 20071161A NO 20071161 A NO20071161 A NO 20071161A NO 20071161 L NO20071161 L NO 20071161L
- Authority
- NO
- Norway
- Prior art keywords
- chemokine
- receptor
- chemical connections
- binding
- ccr5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60192804P | 2004-08-16 | 2004-08-16 | |
| PCT/US2005/028811 WO2006023400A2 (en) | 2004-08-16 | 2005-08-12 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20071161L true NO20071161L (no) | 2007-05-14 |
Family
ID=35968075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20071161A NO20071161L (no) | 2004-08-16 | 2007-03-01 | Kjemiske forbindelser |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080045537A1 (enExample) |
| EP (1) | EP1789045A2 (enExample) |
| JP (1) | JP2008510006A (enExample) |
| KR (1) | KR20070042568A (enExample) |
| CN (1) | CN101039672A (enExample) |
| AR (1) | AR050522A1 (enExample) |
| AU (1) | AU2005277638A1 (enExample) |
| BR (1) | BRPI0514438A (enExample) |
| CA (1) | CA2577100A1 (enExample) |
| IL (1) | IL181160A0 (enExample) |
| MA (1) | MA28814B1 (enExample) |
| MX (1) | MX2007001958A (enExample) |
| NO (1) | NO20071161L (enExample) |
| PE (1) | PE20060646A1 (enExample) |
| RU (1) | RU2350604C2 (enExample) |
| TW (1) | TW200619217A (enExample) |
| WO (1) | WO2006023400A2 (enExample) |
| ZA (1) | ZA200701282B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| US8318931B2 (en) | 2005-10-28 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
| ES2407115T3 (es) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
| JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| CL2008002242A1 (es) * | 2007-07-31 | 2009-08-21 | Bayer Cropscience Ag | Compuestos derivados de n-cicloalquil-n-carboxamida, tiocarboxamida, biciclicas o derivados de carboximidamida n-sustituida; composicion fungicida; y metodo para controlar los hongos fitopatogenos de los cultivos. |
| WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
| JP5541454B2 (ja) * | 2009-09-16 | 2014-07-09 | Ｊｓｒ株式会社 | 液晶配向剤および液晶表示素子 |
| JP5712524B2 (ja) * | 2009-10-28 | 2015-05-07 | Jsr株式会社 | 液晶配向剤および液晶表示素子 |
| MA34591B1 (fr) | 2010-10-06 | 2013-10-02 | Glaxosmithkline Llc | Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase |
| CN102675305B (zh) * | 2011-03-08 | 2014-11-12 | 中国科学院上海药物研究所 | 一类咪唑并吡啶类化合物及其制备方法和用途 |
| CN103570683B (zh) * | 2012-07-30 | 2018-04-17 | 中国科学院上海药物研究所 | 多取代胺类化合物及其制备方法和用途 |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| JP6864296B2 (ja) | 2015-12-14 | 2021-04-28 | エックス４ ファーマシューティカルズ， インコーポレイテッド | がんを処置する方法 |
| WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| EP3440112A4 (en) | 2016-04-08 | 2019-10-09 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| IL309069A (en) | 2017-02-21 | 2024-02-01 | Univ Emory | CXCR4 cytokine receptor modulators and related uses |
| JP7282786B2 (ja) * | 2017-09-25 | 2023-05-29 | シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド | Ｃｘｃｒ４阻害剤としてのヘテロアリール化合物、それを用いた組成物及び方法 |
| WO2019060860A1 (en) * | 2017-09-25 | 2019-03-28 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF |
| EP3768256A4 (en) | 2018-03-19 | 2021-11-24 | Emory University | PANTROPIC ENTRY INHIBITORS |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004512336A (ja) * | 2000-09-15 | 2004-04-22 | アノーメッド インコーポレイティド | ケモカインレセプター結合複素環式化合物 |
| DE60143457D1 (de) * | 2000-09-15 | 2010-12-23 | Anormed Inc | Chemokin Rezeptor bindende heterozyklische Verbindungen |
| IL154227A0 (en) * | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| NZ524421A (en) * | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| CN1596255A (zh) * | 2001-12-21 | 2005-03-16 | 阿诺麦德股份有限公司 | 具有强效的与趋化因子受体结合的杂环化合物 |
| RU2006136381A (ru) * | 2004-03-15 | 2008-04-27 | Анормед, Инк. (Ca) | Способ получения антагониста cxcr4 |
-
2005
- 2005-08-12 AR ARP050103418A patent/AR050522A1/es not_active Application Discontinuation
- 2005-08-12 RU RU2007105823/04A patent/RU2350604C2/ru not_active IP Right Cessation
- 2005-08-12 JP JP2007527895A patent/JP2008510006A/ja active Pending
- 2005-08-12 EP EP05786708A patent/EP1789045A2/en not_active Withdrawn
- 2005-08-12 MX MX2007001958A patent/MX2007001958A/es not_active Application Discontinuation
- 2005-08-12 AU AU2005277638A patent/AU2005277638A1/en not_active Abandoned
- 2005-08-12 US US11/573,729 patent/US20080045537A1/en not_active Abandoned
- 2005-08-12 WO PCT/US2005/028811 patent/WO2006023400A2/en not_active Ceased
- 2005-08-12 KR KR1020077005000A patent/KR20070042568A/ko not_active Withdrawn
- 2005-08-12 TW TW094127423A patent/TW200619217A/zh unknown
- 2005-08-12 CN CNA2005800351651A patent/CN101039672A/zh active Pending
- 2005-08-12 CA CA002577100A patent/CA2577100A1/en not_active Abandoned
- 2005-08-12 BR BRPI0514438-8A patent/BRPI0514438A/pt not_active IP Right Cessation
- 2005-08-12 PE PE2005000940A patent/PE20060646A1/es not_active Application Discontinuation
-
2007
- 2007-02-05 IL IL181160A patent/IL181160A0/en unknown
- 2007-02-13 ZA ZA200701282A patent/ZA200701282B/xx unknown
- 2007-02-21 MA MA29700A patent/MA28814B1/fr unknown
- 2007-03-01 NO NO20071161A patent/NO20071161L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005277638A1 (en) | 2006-03-02 |
| MX2007001958A (es) | 2007-05-09 |
| AR050522A1 (es) | 2006-11-01 |
| ZA200701282B (en) | 2010-05-26 |
| US20080045537A1 (en) | 2008-02-21 |
| RU2350604C2 (ru) | 2009-03-27 |
| TW200619217A (en) | 2006-06-16 |
| RU2007105823A (ru) | 2008-09-27 |
| CN101039672A (zh) | 2007-09-19 |
| WO2006023400A3 (en) | 2006-06-08 |
| MA28814B1 (fr) | 2007-08-01 |
| BRPI0514438A (pt) | 2008-06-10 |
| WO2006023400A2 (en) | 2006-03-02 |
| JP2008510006A (ja) | 2008-04-03 |
| IL181160A0 (en) | 2007-07-04 |
| PE20060646A1 (es) | 2006-08-04 |
| EP1789045A2 (en) | 2007-05-30 |
| KR20070042568A (ko) | 2007-04-23 |
| CA2577100A1 (en) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20071161L (no) | Kjemiske forbindelser | |
| NO20071366L (no) | Kjemiske forbindelser | |
| TW200738711A (en) | Chemical compounds | |
| TW200612935A (en) | Chemical compounds | |
| WO2007027999A3 (en) | Chemical compounds | |
| Goin et al. | Origins, radiations, and distribution of South American mammals: from greenhouse to icehouse worlds | |
| NO20076046L (no) | Bindemidler | |
| WO2007022371A3 (en) | Chemokine receptor binding compounds | |
| MA30531B1 (fr) | Anticorps anti-dll4 et leurs procedes d'utilisation | |
| DK1864132T3 (da) | Fra amnion stammende cellesammensætninger, fremgangsmåder til fremstilling deraf og anvendelser deraf | |
| NO20091326L (no) | Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase | |
| MX2007010272A (es) | Inhibidores de moleculas pequenas de mdm2 y usos de los mismos. | |
| IL221366A (en) | Soluble zb7ri polypeptide and method used | |
| NO20076355L (no) | Dengue serotype 1 attenuert stamme | |
| NO20080062L (no) | Fremgangsmate for pavisning av mikroorganisme og kit for pavisning av mikroorganisme | |
| NO20076391L (no) | Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin | |
| NO20076515L (no) | Hydantoinforbindelser | |
| WO2006076131A3 (en) | Chemical compounds | |
| NO20064134L (no) | Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav | |
| ZA200704260B (en) | Melanocortin receptor binding mimetibodies, compositions, methods and uses | |
| WO2005059107A3 (en) | Chemokine receptor binding compounds | |
| SE0400208D0 (sv) | Chemical compounds | |
| MXPA06012987A (es) | Epitopos inductores de muerte de celulas t. | |
| WO2006138350A3 (en) | Chemokine receptor binding compounds | |
| NO20084579L (no) | Fremgangsmate for vaksinering av individer som mottar immunmodulerende terapi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |